Evidence map›Paper›PMID 40158444›Full record

ArticleBiomaterials2025

Therapeutic potential of urinary extracellular vesicles in delivering functional proteins and modulating gene expression for genetic kidney disease.

Yi Huang, Ali Osouli, Hui Li, Megan Dudaney, Jessica Pham, Valeria Mancino, Taranatee Khan, Baishali Chaudhuri, Nuria M Pastor-Soler, Kenneth R Hallows and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi HuangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
Ali OsouliDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
Hui LiDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; USC/UKRO Kidney Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Megan DudaneyDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
Jessica PhamDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; USC/UKRO Kidney Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Valeria MancinoDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; USC/UKRO Kidney Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Taranatee KhanDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
Baishali ChaudhuriDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
Nuria M Pastor-SolerDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; USC/UKRO Kidney Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Kenneth R HallowsDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; USC/UKRO Kidney Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Eun Ji ChungDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA; Department of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA, USA; Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Bridge Institute, University of Southern California, Los Angeles, CA, USA. Electronic address: eunchung@usc.edu.

Funding

Coordinating Unit for the Innovative Science Accelerator ProgramU24DK128851 · NIDDK · AUGUSTA UNIVERSITY · PI MCINDOE, RICHARD A. · 2021 to 2025
$6.7M
A Revolutionary Approach for Polycystic Kidney Disease: Oral NanotherapeuticsDP2DK121328 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUNG, EUN JI PAIGE · 2018 to 2018
$2.4M
Investigation of urinary extracellular vesicles as novel and safe therapeutics for autosomal recessive polycystic kidney diseaseR21HD113263 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUNG, EUN JI PAIGE · 2023 to 2023
$466k
NICHD NIH HHS R21 HD113263NIDDK NIH HHS DP2 DK121328NIDDK NIH HHS U24 DK128851
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a widespread health concern, impacting approximately 600 million individuals worldwide and marked by a progressive decline in kidney function. A common form of CKD is autosomal dominant polycystic kidney disease (ADPKD), which is the most inherited genetic kidney disease and affects greater than 12.5 million individuals globally. Given that there are over 400 pathogenic PKD1/PKD2 mutations in patients with ADPKD, relying solely on small molecule drugs targeting a single signaling pathway has not been effective in treating ADPKD. Urinary extracellular vesicles (uEVs) are naturally released by cells from the kidneys and the urinary tract, and uEVs isolated from non-disease sources have been reported to carry functional polycystin-1 (PC1) and polycystin-2 (PC2), the respective products of PKD1 and PKD2 genes that are mutated in ADPKD. uEVs from non-disease sources, as a result, have the potential to provide a direct solution to the root of the disease by delivering functional proteins that are mutated in ADPKD. To test our hypothesis, we first isolated uEVs from healthy mice urine and conducted a comprehensive characterization of uEVs. Then, PC1 levels and EV markers CD63 and TSG101 of uEVs were confirmed via ELISA and Western blot. Following characterization of uEVs, the in vitro cellular uptake, inhibition of cyst growth, and gene rescue ability of uEVs were demonstrated in kidney cells. Next, upon administration of uEVs in vivo, uEVs showed bioavailability and accumulation in the kidneys. Lastly, uEV treatment in ADPKD mice (Pkd1

Indexed as

Extracellular VesiclesPolycystic Kidney, Autosomal DominantAnimalsEndosomal Sorting Complexes Required for TransportHumansKidneyMaleMiceMice, Inbred C57BLTRPP Cation ChannelsEndosomal Sorting Complexes Required for TransportTRPP Cation ChannelsExtracellular vesicleGene therapyKidney diseaseNanomedicineProtein therapy

Identifiers

PMID40158444
PMCPMC12048220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.